Literature DB >> 13197751

Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

W McDERMOTT, R TOMPSETT.   

Abstract

Entities:  

Keywords:  MYCOBACTERIUM TUBERCULOSIS/effect of drugs on; NICOTINIC ACID/derivatives

Mesh：

Substances：

Year:  1954        PMID： 13197751     DOI： 10.1164/art.1954.70.4.748

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  100 in total

1.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia.

Authors:  H J Marttila; M Marjamäki; E Vyshnevskaya; B I Vyshnevskiy; T F Otten; A V Vasilyef; M K Viljanen
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.

Authors:  A P Davies; O J Billington; T D McHugh; D A Mitchison; S H Gillespie
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

3.  In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.

Authors:  Prakash M Jeena; William R Bishai; Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

4.  Use of HeLa cells infected with tubercle bacilli for the study of antituberculous drugs.

Authors:  C C SHEPARD
Journal:  J Bacteriol       Date:  1957-04       Impact factor: 3.490

5.  The current status of the development of antimicrobial agents.

Authors:  G L HOBBY
Journal:  Bull N Y Acad Med       Date:  1955-03

6.  Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Niuris C Mirabal; Sergio L Yzquierdo; Dihadenys Lemus; Mariela Madruga; Yoslaine Milián; Miguel Echemendía; Howard Takiff; Anandi Martin; Patrick Van der Stuyf; Juan Carlos Palomino; Ernesto Montoro
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

7.  Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors:  Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

8.  Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth.

Authors:  L B Heifets; M D Iseman
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

10.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.